Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Sonia Maria Rolim Rosa Lima"
We found (12) results for your search.Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1999;21(3):127-131
DOI 10.1590/S0100-72031999000300002
Purpose: the frequency of point mutation at codon 12 of the K¾ras gene was determined in paraffin blocks of surgical specimens from patients who had ductal invasive breast cancer. Material and Methods: Fifty surgical specimens blocked in paraffin from patients with ductal invasive breast cancer, with histological degree II and III, were used. The polymerase chain reaction (PCR) was used for amplification of DNA fragments studied. The material cleavage was obtained with restriction fragment length polymorphisms (RFLP). The electrophoresis in agarose gel, with Ladder 123 (GIBCO-BRL) marker, was employed to verify if some mutation had occurred. The results were shown using ultraviolet beam and recorded by photos. Results: mutations at codon 12 of K-ras gene were found in five samples (10%) and all of them were polymorphic for this caracter. The five patients whose tumors expressed mutation were in the postmenopausal period. Four patientes had tumors of histological degree II and one, III.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1999;21(3):127-131
DOI 10.1590/S0100-72031999000300002
Purpose: the frequency of point mutation at codon 12 of the K¾ras gene was determined in paraffin blocks of surgical specimens from patients who had ductal invasive breast cancer. Material and Methods: Fifty surgical specimens blocked in paraffin from patients with ductal invasive breast cancer, with histological degree II and III, were used. The polymerase chain reaction (PCR) was used for amplification of DNA fragments studied. The material cleavage was obtained with restriction fragment length polymorphisms (RFLP). The electrophoresis in agarose gel, with Ladder 123 (GIBCO-BRL) marker, was employed to verify if some mutation had occurred. The results were shown using ultraviolet beam and recorded by photos. Results: mutations at codon 12 of K-ras gene were found in five samples (10%) and all of them were polymorphic for this caracter. The five patients whose tumors expressed mutation were in the postmenopausal period. Four patientes had tumors of histological degree II and one, III.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2009;31(3):131-137
DOI 10.1590/S0100-72032009000300005
PURPOSE: to evaluate the effects of tamoxifen on the expression of TGF-β and p27 proteins in polyps and adjacent endometrium of women after menopause. METHODS: prospective study with 30 post-menopausal women with diagnosis of breast cancer, taking tamoxifen (20 mg/day), presenting diagnosis of suspect endometrial polyps through transvaginal ultrasonography, and submitted to diagnostic and surgical hysterectomy to withdraw the polyps and adjacent endometrium. A immunohistochemical study has been done to verify the expression of the TGF-β and p27 proteins in the polyps and adjacent endometrium. These proteins' quantification has been done by morphometry. RESULTS: the patients' average age was 61.7 years old; their average age at the menopause onset was 49.5; and the average of using tamoxifen was 25.3 months. The average concentration of positive cells for TGF-β protein in the glandular and stroma polyp epithelium was 62.6±4.5 cells/mm². For the p27, in the glandular polyp epithelium, it was 24.2±18.6 cells/mm² and for the stroma, 19.2±15.2 cells/mm². There was no significant difference between the expression of TGF-β and p27 in the glandular epithelial form the polyps and the adjacent endometrium. The expression of proteins in the polyp and adjacent endometrium with its respective glandular and stroma epithelium showed a significant difference for the p27 protein (r=0.9, p<0.05). CONCLUSIONS: we have concluded that the TGF-β expression is not related to the effect of tamoxifen on the growing of endometrial polyps, but the absence of polyps' malignization by tamoxifen may be explained by the high expression of p27 protein in its glandular epithelium.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2009;31(3):131-137
DOI 10.1590/S0100-72032009000300005
PURPOSE: to evaluate the effects of tamoxifen on the expression of TGF-β and p27 proteins in polyps and adjacent endometrium of women after menopause. METHODS: prospective study with 30 post-menopausal women with diagnosis of breast cancer, taking tamoxifen (20 mg/day), presenting diagnosis of suspect endometrial polyps through transvaginal ultrasonography, and submitted to diagnostic and surgical hysterectomy to withdraw the polyps and adjacent endometrium. A immunohistochemical study has been done to verify the expression of the TGF-β and p27 proteins in the polyps and adjacent endometrium. These proteins' quantification has been done by morphometry. RESULTS: the patients' average age was 61.7 years old; their average age at the menopause onset was 49.5; and the average of using tamoxifen was 25.3 months. The average concentration of positive cells for TGF-β protein in the glandular and stroma polyp epithelium was 62.6±4.5 cells/mm². For the p27, in the glandular polyp epithelium, it was 24.2±18.6 cells/mm² and for the stroma, 19.2±15.2 cells/mm². There was no significant difference between the expression of TGF-β and p27 in the glandular epithelial form the polyps and the adjacent endometrium. The expression of proteins in the polyp and adjacent endometrium with its respective glandular and stroma epithelium showed a significant difference for the p27 protein (r=0.9, p<0.05). CONCLUSIONS: we have concluded that the TGF-β expression is not related to the effect of tamoxifen on the growing of endometrial polyps, but the absence of polyps' malignization by tamoxifen may be explained by the high expression of p27 protein in its glandular epithelium.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(3):140-146
The aim of this study was to study the effects of Tribulus terrestris on sexual function in menopausal women.
This was a prospective, randomized, double-blind, placebo-controlled clinical trial that included 60 postmenopausal women with sexual dysfunction. The women were divided into two groups, placebo group and Tribulus group, and evaluated by using the Sexual Quotient-female version (SQ-F) and Female Intervention Efficacy Index (FIEI) questionnaires.
There was no significant difference between the groups in age, age at menopause, civil status, race, and religion. In the evaluation with the SQ-F questionnaire, there were significant differences between the placebo (7.6±3.2) and Tribulus (10.2±3.2) groups in the domains of desire and sexual interest (p d" 0.001), foreplay (3.3±1.5 versus 4.2±1.0) (p d" 0.01), arousal and harmonious interaction with the partner (5.7±2.1 versus 7.2±2.6) (p d" 0.01), and comfort in sexual intercourse (6.5±2.4 versus 8.0±1.9) (p d" 0.01). There was no significant difference between the placebo and Tribulus groups in the domains of orgasm and sexual satisfaction (p = 0.28). In the FIEI questionnaire, there was a significant improvement (p < 0.001) in the domains of vaginal lubrication during coitus and/or foreplay (20 versus 83.3%), sensation in the genitalia during sexual intercourse or other stimuli (16.7 versus 76.7%), sensation in the genital region (20 versus 70%), sexual intercourse and/or other sexual stimulations (13.3 versus 43.3%), and the ability to reach orgasm (20% versus 73.3%). There was no significant difference in adverse effects between the two groups.
After 90 days of treatment, at the doses used, we found Tribulus terrestris to be effective in treating sexual problems among menopausal women.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(3):140-146
The aim of this study was to study the effects of Tribulus terrestris on sexual function in menopausal women.
This was a prospective, randomized, double-blind, placebo-controlled clinical trial that included 60 postmenopausal women with sexual dysfunction. The women were divided into two groups, placebo group and Tribulus group, and evaluated by using the Sexual Quotient-female version (SQ-F) and Female Intervention Efficacy Index (FIEI) questionnaires.
There was no significant difference between the groups in age, age at menopause, civil status, race, and religion. In the evaluation with the SQ-F questionnaire, there were significant differences between the placebo (7.6±3.2) and Tribulus (10.2±3.2) groups in the domains of desire and sexual interest (p d" 0.001), foreplay (3.3±1.5 versus 4.2±1.0) (p d" 0.01), arousal and harmonious interaction with the partner (5.7±2.1 versus 7.2±2.6) (p d" 0.01), and comfort in sexual intercourse (6.5±2.4 versus 8.0±1.9) (p d" 0.01). There was no significant difference between the placebo and Tribulus groups in the domains of orgasm and sexual satisfaction (p = 0.28). In the FIEI questionnaire, there was a significant improvement (p < 0.001) in the domains of vaginal lubrication during coitus and/or foreplay (20 versus 83.3%), sensation in the genitalia during sexual intercourse or other stimuli (16.7 versus 76.7%), sensation in the genital region (20 versus 70%), sexual intercourse and/or other sexual stimulations (13.3 versus 43.3%), and the ability to reach orgasm (20% versus 73.3%). There was no significant difference in adverse effects between the two groups.
After 90 days of treatment, at the doses used, we found Tribulus terrestris to be effective in treating sexual problems among menopausal women.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(1):18-23
DOI 10.1590/S0100-72032006000100004
PURPOSE: to characterize postmenopausal endometrial polyps and to determine risk for concomitant premalignant and malignant pathology. METHODS: a retrospective study including 82 postmenopausal women with a histological diagnosis of endometrial polyps who underwent hysteroscopic polypectomy, after a diagnosis of endometrial thickening made by transvaginal ultrasound, was performed. Medical reports provided clinical and gynecological history, data related to the operative hysteroscopy and definitive histological findings. RESULTS: among the 82 patients who underwent hysteroscopic polypectomy, 10.9% were receiving some type of hormonal therapy. Twenty-eight women (34.1%) reported abnormal vaginal bleeding. Single polyp was encountered in 56 women (68.3%), two polyps were found in 19 cases (23.2%) and in 7 cases (3.6%), three or more polyps were found. The definitive histopathologic analysis revealed 63 (76.8%) benign polyps, 17 (20.8%) hyperplastic polyps (10 cases 12.2% - of simple endometrial hyperplasia without cytologic atypia and 7 cases 8.6% - of complex endometrial hyperplasia without cytologic atypia). Two polyps (2.4%) were diagnosed as harboring neoplasia. For the statistical analysis we employed chi2 test improved by Yates. The authors correlated the polyps' histology with the occurrence of abnormal vaginal bleeding (p=0.0056), number of endometrial polyps (p=0.921) and time after menopause (p=0.720). CONCLUSIONS: endometrial polyps are commonly found entities in postmenopausal women, related with low frequency to endometrial hyperplasia or carcinomas and only histological evaluation seems to allow the exclusion of premalignant and malignant pathology.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(1):18-23
DOI 10.1590/S0100-72032006000100004
PURPOSE: to characterize postmenopausal endometrial polyps and to determine risk for concomitant premalignant and malignant pathology. METHODS: a retrospective study including 82 postmenopausal women with a histological diagnosis of endometrial polyps who underwent hysteroscopic polypectomy, after a diagnosis of endometrial thickening made by transvaginal ultrasound, was performed. Medical reports provided clinical and gynecological history, data related to the operative hysteroscopy and definitive histological findings. RESULTS: among the 82 patients who underwent hysteroscopic polypectomy, 10.9% were receiving some type of hormonal therapy. Twenty-eight women (34.1%) reported abnormal vaginal bleeding. Single polyp was encountered in 56 women (68.3%), two polyps were found in 19 cases (23.2%) and in 7 cases (3.6%), three or more polyps were found. The definitive histopathologic analysis revealed 63 (76.8%) benign polyps, 17 (20.8%) hyperplastic polyps (10 cases 12.2% - of simple endometrial hyperplasia without cytologic atypia and 7 cases 8.6% - of complex endometrial hyperplasia without cytologic atypia). Two polyps (2.4%) were diagnosed as harboring neoplasia. For the statistical analysis we employed chi2 test improved by Yates. The authors correlated the polyps' histology with the occurrence of abnormal vaginal bleeding (p=0.0056), number of endometrial polyps (p=0.921) and time after menopause (p=0.720). CONCLUSIONS: endometrial polyps are commonly found entities in postmenopausal women, related with low frequency to endometrial hyperplasia or carcinomas and only histological evaluation seems to allow the exclusion of premalignant and malignant pathology.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(1):27-33
DOI 10.1590/S0100-72032007000100005
PURPOSE: to evaluate oxidative stress in cardiac tissue of ovariectomized rats, with and without hormonal therapy. METHODS: female Wistar rats were divided in three groups: control group (CG); ovariectomized group (OG); ovariectomized group with estrogen supplementation (ESG). The estrogen deprivation was done through bilateral ovariectomy. After one week from the ovariectomy, a pellet of 1.5 mg of 17beta-estradiol was implanted in the ESG animals. Nine weeks after the ovariectomy, cardiac tissue was obtained for the analysis of the oxidative stress through CL (chemiluminescence), and measurement of antioxidant enzymes catalase (CAT), superoxide dismutase (SOD) and gluthatione peroxidase (GPx). RESULTS: CL was increased in the OG (7348±312 cps/mg protein) when compared with the CG (6250±41 cps/mg protein, p<0.01), but there was no significant difference between the CG and the ESG (6170±237 cps/mg protein). Ovariectomy reduced SOD (35%, p<0.05) and CAT (22%, p<0.001) activities in the OG as compared with the CG. Hormonal therapy normalized antioxidant enzymes activities in the ESG. There was no statistically significant difference in GPx activity among the groups studied. CONCLUSIONS: ovarian hormone deprivation induced an increase of oxidative stress with reduction of antioxidant defenses in the cardiac tissue. However, hormonal therapy prevented oxidative stress after ovariectomy, probably due to an increase of the CAT and SOD activities in the cardiac muscle. These findings suggest an important oxidative stress contribution in cardiovascular dysfunctions observed in women after menopause, reinforcing the importance of hormonal therapy in the management of cardiovascular diseases risk in this group of women.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(1):27-33
DOI 10.1590/S0100-72032007000100005
PURPOSE: to evaluate oxidative stress in cardiac tissue of ovariectomized rats, with and without hormonal therapy. METHODS: female Wistar rats were divided in three groups: control group (CG); ovariectomized group (OG); ovariectomized group with estrogen supplementation (ESG). The estrogen deprivation was done through bilateral ovariectomy. After one week from the ovariectomy, a pellet of 1.5 mg of 17beta-estradiol was implanted in the ESG animals. Nine weeks after the ovariectomy, cardiac tissue was obtained for the analysis of the oxidative stress through CL (chemiluminescence), and measurement of antioxidant enzymes catalase (CAT), superoxide dismutase (SOD) and gluthatione peroxidase (GPx). RESULTS: CL was increased in the OG (7348±312 cps/mg protein) when compared with the CG (6250±41 cps/mg protein, p<0.01), but there was no significant difference between the CG and the ESG (6170±237 cps/mg protein). Ovariectomy reduced SOD (35%, p<0.05) and CAT (22%, p<0.001) activities in the OG as compared with the CG. Hormonal therapy normalized antioxidant enzymes activities in the ESG. There was no statistically significant difference in GPx activity among the groups studied. CONCLUSIONS: ovarian hormone deprivation induced an increase of oxidative stress with reduction of antioxidant defenses in the cardiac tissue. However, hormonal therapy prevented oxidative stress after ovariectomy, probably due to an increase of the CAT and SOD activities in the cardiac muscle. These findings suggest an important oxidative stress contribution in cardiovascular dysfunctions observed in women after menopause, reinforcing the importance of hormonal therapy in the management of cardiovascular diseases risk in this group of women.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2013;35(7):301-308
DOI 10.1590/S0100-72032013000700004
PURPOSE: To evaluate sexual function in postmenopausal women diagnosed with metabolic syndrome. METHODS: Case-control study with 195 postmenopausal women (amenorrhea ≥1 year, FSH≥30 mIU/mL, aged 43 to 69 years) seen at the Department of Obstetrics and Gynecology, School of Medical Sciences of Santa Casa de São Paulo and in the Basic Units of the Family Health Program of São Paulo. Clinical data were collected, and body mass index and waist circumference were evaluated. Total cholesterol, HDL and LDL cholesterols, triglycerides, and fasting glucose were determined for biochemical analysis. We considered women to have the metabolic syndrome when they met three or more diagnostic criteria: waist circumference>88 cm and triglycerides ≥150 mg/dL; cholesterol HDL <50 mg/dL; blood pressure ≥130/85 mmHg, and fasting glucose ≥110 mg/dL. The participants were divided into Control Group (n=87) and Metabolic Syndrome Group (n=108). The Female Sexual Function Index (FSFI) was employed to assess the sexual function. RESULTS: Mean age was 54.0±4.7 years. The rate of sexual dysfunction was significantly higher in women with the metabolic syndrome than in the Control Group, both when considering FSFI <26.5 (90/108 [83.3%] versus 42/87 [48.2%], p<0.0001) and FSFI <23 (62/108 [57.4%] versus 16/87 [18.39%], p<0.001). The domains desire, arousal, lubrication, orgasm (p<0.001), and satisfaction (p=0.002) had lower scores in women with the metabolic syndrome. For the pain scores, there was no significant difference (p=0.57) between groups. All components of the metabolic syndrome diagnosis were associated with higher levels of sexual dysfunction (p<0.001). CONCLUSION: Postmenopausal women with metabolic syndrome present more frequently sexual dysfunction than those of the same age who do not have it.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2013;35(7):301-308
DOI 10.1590/S0100-72032013000700004
PURPOSE: To evaluate sexual function in postmenopausal women diagnosed with metabolic syndrome. METHODS: Case-control study with 195 postmenopausal women (amenorrhea ≥1 year, FSH≥30 mIU/mL, aged 43 to 69 years) seen at the Department of Obstetrics and Gynecology, School of Medical Sciences of Santa Casa de São Paulo and in the Basic Units of the Family Health Program of São Paulo. Clinical data were collected, and body mass index and waist circumference were evaluated. Total cholesterol, HDL and LDL cholesterols, triglycerides, and fasting glucose were determined for biochemical analysis. We considered women to have the metabolic syndrome when they met three or more diagnostic criteria: waist circumference>88 cm and triglycerides ≥150 mg/dL; cholesterol HDL <50 mg/dL; blood pressure ≥130/85 mmHg, and fasting glucose ≥110 mg/dL. The participants were divided into Control Group (n=87) and Metabolic Syndrome Group (n=108). The Female Sexual Function Index (FSFI) was employed to assess the sexual function. RESULTS: Mean age was 54.0±4.7 years. The rate of sexual dysfunction was significantly higher in women with the metabolic syndrome than in the Control Group, both when considering FSFI <26.5 (90/108 [83.3%] versus 42/87 [48.2%], p<0.0001) and FSFI <23 (62/108 [57.4%] versus 16/87 [18.39%], p<0.001). The domains desire, arousal, lubrication, orgasm (p<0.001), and satisfaction (p=0.002) had lower scores in women with the metabolic syndrome. For the pain scores, there was no significant difference (p=0.57) between groups. All components of the metabolic syndrome diagnosis were associated with higher levels of sexual dysfunction (p<0.001). CONCLUSION: Postmenopausal women with metabolic syndrome present more frequently sexual dysfunction than those of the same age who do not have it.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2002;24(5):349-349
DOI 10.1590/S0100-72032002000500011
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2002;24(5):349-349
DOI 10.1590/S0100-72032002000500011
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2002;24(1):45-50
DOI 10.1590/S0100-72032002000100007
Purpose: to perform a census about the frequency of endometrial adenocarcinoma of women submitted to diagnostic hysteroscopy in five Brazilian hysteroscopic centers in São Paulo, Rio de Janeiro, Salvador, Caxias do Sul and Porto Alegre. Methods: information was collected from standard questionnaires about the presence of endometrial adenocarcinoma, hysteroscopic staging and histologic type, in pre- and postmenopausal women. Results: among 6,466 hysteroscopic procedures, endometrial adenocarcinoma was present in 92 patients (1.4%), confirmed by histology in 79 (1.2%) cases. For the hysteroscopic diagnosis of endometrial adenocarcinoma confirmed by histology, a sensitivity of 85.9%, specificity of 100%, positive predictive value of 100% and negative predictive value of 98.6% were obtained. In the premenopausal group, among 3,845 hysteroscopic exams, endometrial cancer was present in 83 (3.2%) and confirmed by histology in 71 cases (2.7%). Conclusions: this study points out the importance of epidemiological methods in the diagnostic and prevention programs of endometrial cancer, specially in postmenopause, revealing the need for further epidemiological studies on endometrial adenocarcinoma diagnostis and prevention programs.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2002;24(1):45-50
DOI 10.1590/S0100-72032002000100007
Purpose: to perform a census about the frequency of endometrial adenocarcinoma of women submitted to diagnostic hysteroscopy in five Brazilian hysteroscopic centers in São Paulo, Rio de Janeiro, Salvador, Caxias do Sul and Porto Alegre. Methods: information was collected from standard questionnaires about the presence of endometrial adenocarcinoma, hysteroscopic staging and histologic type, in pre- and postmenopausal women. Results: among 6,466 hysteroscopic procedures, endometrial adenocarcinoma was present in 92 patients (1.4%), confirmed by histology in 79 (1.2%) cases. For the hysteroscopic diagnosis of endometrial adenocarcinoma confirmed by histology, a sensitivity of 85.9%, specificity of 100%, positive predictive value of 100% and negative predictive value of 98.6% were obtained. In the premenopausal group, among 3,845 hysteroscopic exams, endometrial cancer was present in 83 (3.2%) and confirmed by histology in 71 cases (2.7%). Conclusions: this study points out the importance of epidemiological methods in the diagnostic and prevention programs of endometrial cancer, specially in postmenopause, revealing the need for further epidemiological studies on endometrial adenocarcinoma diagnostis and prevention programs.
